Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
- 31 January 2012
- journal article
- research article
- Published by Elsevier BV in European Journal of Cancer
- Vol. 48 (2), 253-262
- https://doi.org/10.1016/j.ejca.2011.09.021
Abstract
No abstract availableThis publication has 32 references indexed in Scilit:
- Epidemiology of childhood cancerCancer Treatment Reviews, 2010
- Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First CenturyJournal of Clinical Oncology, 2010
- Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell GrowthSeminars in Oncology, 2009
- Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing ConsiderationsSeminars in Oncology, 2009
- Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignanciesLeukemia & Lymphoma, 2009
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell LymphomaJournal of Clinical Oncology, 2009
- Long-Term Outcomes Among Adult Survivors of Childhood Central Nervous System Malignancies in the Childhood Cancer Survivor StudyJNCI Journal of the National Cancer Institute, 2009
- Late Mortality Among 5-Year Survivors of Childhood Cancer: A Summary From the Childhood Cancer Survivor StudyJournal of Clinical Oncology, 2009
- A New Pharmacologic Action of CCI-779 Involves FKBP12-Independent Inhibition of mTOR Kinase Activity and Profound Repression of Global Protein SynthesisCancer Research, 2008
- Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivoOncogene, 2007